Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Drugs (New York, N.Y.) N.Y.), 2011-02, Vol.71 (3), p.255-261
Hauptverfasser:	Saylor, Philip J., Keating, Nancy L., Freedland, Stephen J., Smith, Matthew R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Androgen Antagonists - adverse effects Androgen Antagonists - therapeutic use Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cardiovascular diseases Cardiovascular Diseases - complications Cardiovascular Diseases - epidemiology Complications and side effects Development and progression Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - epidemiology Dosage and administration Drug therapy Editorial Gonadotropin-Releasing Hormone - agonists Hormone antagonists Humans Incidence Internal Medicine Male Medicine Medicine & Public Health Patient outcomes Pharmacology/Toxicology Pharmacotherapy Prostate cancer Prostatic Neoplasms - complications Prostatic Neoplasms - drug therapy Risk Factors Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!